EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study

Eyal Lebel, Efstathios Kastritis iD, Giovanni Palladini iD, Paolo Milani, Foteini Theodorakakou iD, Shlomzion Aumann, Noa Lavi, Liat Shargian, Hila Magen iD, Yael Cohen, Moshe E Gatt iD, Iuliana Vaxman

Cancers · 10.03.2023 · 15 (6) · 1710

DOI: 10.3390/cancers15061710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 10.03.2023. Verfasst von Eyal Lebel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic options in relapsed refractory (R/R) light-chain (AL) amyloidosis patients are limited. Given the encouraging results in t(11;14) multiple myeloma and the high prevalence of t(11;14) in AL amyloidosis, venetoclax is an attractive treatment option in this setting. We report here the results of a multi-center retrospective study on 26 R/R AL amyloidosis patients treated off-label with venetoclax. The median lines of therapy prior to venetoclax was 3.5 (range 1–7), and 88% of our cohort had t (11;14). Twenty-two patients (85%) were previously treated with daratumumab. The overall hematologic response rate was 88%, 35% achieved a CR, and 35% achieved VGPR. The median event-free survival was 25 months (m) (95% CI 9.7 m-not reached), and the median overall survival was 33 m (95% CI 25.9–39.2 m). Most of the patients in this cohort are in ongoing deep responses and continuing venetoclax therapy. The treatment was relatively safe. One patient died due to infection, and there were two grade 3 infections in our cohort. Tumor lysis syndrome (TLS) was not seen in any patient. Dose reductions were frequent but did not affect the efficacy. These promising results require confirmation in a randomized controlled trial.

Schlagwörter

Stichwörter der Autor:innen

14)amyloidosist(11venetoclax

Autor:innen und Institutionen

  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
  • Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel.
  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, GR 34400 Athens, Greece.
  • Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
  • Department of Hematology, Rambam Health Care Campus, Haifa 3109601, Israel.

ORCID-Profile: Efstathios Kastritis, Giovanni Palladini, Foteini Theodorakakou, Hila Magen, Moshe E Gatt

Zitieren

APA

Lebel, E., Kastritis, E., Palladini, G., Milani, P., Theodorakakou, F., Aumann, S., Lavi, N., Shargian, L., Magen, H., Cohen, Y., Gatt, M. E., & Vaxman, I. (2023). Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study. Cancers, 15(6), 1710. https://doi.org/10.3390/cancers15061710

Vancouver

Lebel E, Kastritis E, Palladini G, Milani P, Theodorakakou F, Aumann S, et al. Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study. Cancers. 2023;15(6):1710. doi:10.3390/cancers15061710

BibTeX
@article{Lebel2023,
  author = {Lebel, Eyal and Kastritis, Efstathios and Palladini, Giovanni and Milani, Paolo and Theodorakakou, Foteini and Aumann, Shlomzion and Lavi, Noa and Shargian, Liat and Magen, Hila and Cohen, Yael and Gatt, Moshe E and Vaxman, Iuliana},
  title = {Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1710},
  doi = {10.3390/cancers15061710}
}
Kostenlos starten →